iTeos Therapeutics SA, a Gosselies, Belgium-based drug discovery company for immunomodulators, received a €2.94m non-dilutive funding.
The Walloon Region of Belgium provided the grant.
The company intends to use the funds to expand its preclinical drug discovery pipeline targeting new immunotherapies for the tumor micro-environment.
Led by Michel Detheux Ph.D., chief executive officer, and Christophe Quéva Ph.D., chief scientific officer, iTeos has built a discovery platform to identify therapeutics targeting the immune tumor micro-environment to optimize cancer immunotherapy.
The company, which combines expertise in tumor immunology, cancer immunotherapy and drug discovery, entered into a strategic collaboration with Pfizer in December 2014 and is developing partnerships with charities, academic and industrial partners to develop new programs.
A spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), iTeos is also supported by the FEDER (European Fund for Economic and Regional Development).